US Patent

US10059714 — Protein kinase B inhibitors

Composition of Matter · Assigned to AstraZeneca AB · Expires 2028-10-10 · 2y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a novel group of compounds that can be used to treat or prevent diseases mediated by protein kinase B (PKB), such as cancer.

USPTO Abstract

The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z 1 , Z 2 , R 1 , R 4 , R 5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).

Drugs covered by this patent

Patent Metadata

Patent number
US10059714
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-10-10
Drug substance claim
Yes
Drug product claim
Yes
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.